newsfilter
← Latest News
GlobeNewswire·

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response (uPR) that was observed in the first scan has been achieved at